BRPI0415767A - antagonistas de receptor de ccr-3 - Google Patents
antagonistas de receptor de ccr-3Info
- Publication number
- BRPI0415767A BRPI0415767A BRPI0415767-2A BRPI0415767A BRPI0415767A BR PI0415767 A BRPI0415767 A BR PI0415767A BR PI0415767 A BRPI0415767 A BR PI0415767A BR PI0415767 A BRPI0415767 A BR PI0415767A
- Authority
- BR
- Brazil
- Prior art keywords
- ccr
- receptor antagonists
- compounds
- nep
- useful
- Prior art date
Links
- 102000004499 CCR3 Receptors Human genes 0.000 title abstract 3
- 108010017316 CCR3 Receptors Proteins 0.000 title abstract 3
- 239000002464 receptor antagonist Substances 0.000 title abstract 3
- 229940044551 receptor antagonist Drugs 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 102100024167 C-C chemokine receptor type 3 Human genes 0.000 abstract 1
- 101710149862 C-C chemokine receptor type 3 Proteins 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/30—Oxygen or sulfur atoms
- C07D233/32—One oxygen atom
- C07D233/36—One oxygen atom with hydrocarbon radicals, substituted by nitrogen atoms, attached to ring nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/30—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
- C07D239/80—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D277/82—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
"ANTAGONISTAS DE RECEPTOR DE CCR-3". A presente invenção refere-se a compostos de Fórmula (I): onde R¬ 2¬, R¬ 3¬, R¬ 4¬, R¬ 9¬, Ar, U~ c~, X, Y, Q, n e p são como definidos no relatório descritivo. Os compostos são úteis como antagonistas de receptor de CCR-3 e, portanto, poderão ser usados para tratamento de doenças mediadas por CCR-3.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US51429603P | 2003-10-24 | 2003-10-24 | |
| PCT/EP2004/011545 WO2005040129A2 (en) | 2003-10-24 | 2004-10-14 | Ccr3 receptor antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0415767A true BRPI0415767A (pt) | 2006-12-26 |
Family
ID=34520190
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0415767-2A BRPI0415767A (pt) | 2003-10-24 | 2004-10-14 | antagonistas de receptor de ccr-3 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20050090504A1 (pt) |
| EP (1) | EP1680408A2 (pt) |
| JP (1) | JP2007509095A (pt) |
| KR (1) | KR20060061393A (pt) |
| CN (1) | CN1871222A (pt) |
| AR (1) | AR046340A1 (pt) |
| AU (1) | AU2004283842A1 (pt) |
| BR (1) | BRPI0415767A (pt) |
| CA (1) | CA2543419A1 (pt) |
| MX (1) | MXPA06004304A (pt) |
| RU (1) | RU2006117631A (pt) |
| SG (1) | SG131946A1 (pt) |
| TW (1) | TW200522957A (pt) |
| WO (1) | WO2005040129A2 (pt) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2354124E (pt) | 2006-12-19 | 2013-04-09 | Hoffmann La Roche | Derivados de heteroaril-pirrolidinilo e piperidinil-cetona |
| MX2010013447A (es) * | 2008-06-18 | 2010-12-22 | Hoffmann La Roche | Aril-cetonas como inhibidores de reabsorcion de monoaminas. |
| US8278302B2 (en) * | 2009-04-08 | 2012-10-02 | Boehringer Ingelheim International Gmbh | Substituted piperidines as CCR3 antagonists |
| WO2010129351A1 (en) | 2009-04-28 | 2010-11-11 | Schepens Eye Research Institute | Method to identify and treat age-related macular degeneration |
| US8445674B2 (en) * | 2009-10-21 | 2013-05-21 | Hoffmann-La Roche Inc | Heterocyclyl compounds |
| CN102050809B (zh) * | 2009-11-03 | 2014-12-17 | 中国医学科学院药物研究所 | 拮抗cklf1/ccr4相互作用的3-哌嗪基香豆素衍生物 |
| UA109290C2 (uk) | 2010-10-07 | 2015-08-10 | Спільні кристали і солі інгібіторів ccr3 | |
| US10213421B2 (en) | 2012-04-04 | 2019-02-26 | Alkahest, Inc. | Pharmaceutical formulations comprising CCR3 antagonists |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1401549A (en) * | 1972-07-07 | 1975-07-16 | Hisamitsu Pharmaceutical Co | Pyrido-2,3-d-pyrimidine-2,4-1h,3h- diones and methods of preparing them |
| US3922275A (en) * | 1972-11-09 | 1975-11-25 | Hisamitsu Pharmaceutical Co | Pyrido{8 2,3-D{9 {0 pyrimidine-2,4(1H,3H)-diones |
| US4335127A (en) * | 1979-01-08 | 1982-06-15 | Janssen Pharmaceutica, N.V. | Piperidinylalkyl quinazoline compounds, composition and method of use |
| DE3172006D1 (en) * | 1980-05-22 | 1985-10-03 | Masayuki Ishikawa | Novel quinazoline-dione compounds, process for production thereof and pharmaceutical use thereof |
| US4839374A (en) * | 1984-01-09 | 1989-06-13 | Janssen Pharmaceutica, N.V. | 4-((Bicyclic heterocyclyl)-methyl and -hetero)-piperidines |
| US4695575A (en) * | 1984-11-13 | 1987-09-22 | Janssen Pharmaceutica, N.V. | 4-[(bicycle heterocyclyl)-methyl and -hetero]-piperidines |
| JPH0615529B2 (ja) * | 1985-04-01 | 1994-03-02 | エーザイ株式会社 | 新規ピペリジン誘導体 |
| US5143923B1 (en) * | 1991-04-29 | 1993-11-02 | Hoechst-Roussel Pharmaceuticals Incorporated | Benzoisothiazole-and benzisoxazole-3-carboxamides |
| US6126964A (en) * | 1996-01-04 | 2000-10-03 | Mirus Corporation | Process of making a compound by forming a polymer from a template drug |
| AU3906997A (en) * | 1996-08-01 | 1998-02-25 | Isis Pharmaceuticals, Inc. | Novel heterocycle compositions |
| FR2753970B1 (fr) * | 1996-10-01 | 1998-10-30 | Synthelabo | Derives de n-(benzothiazol-2-yl) piperidine-1-ethanamine, leur preparation et leur application en therapeutique |
| IL125658A0 (en) * | 1997-08-18 | 1999-04-11 | Hoffmann La Roche | Ccr-3 receptor antagonists |
| US6084098A (en) * | 1999-02-26 | 2000-07-04 | Neurogen Corporation | Benzylpiperazinyl and piperidinyl ethanone derivatives: dopamine receptor subtype specific ligands |
| CN1325397A (zh) * | 1998-09-30 | 2001-12-05 | 纽罗根公司 | 2-哌嗪烷基氨基苯并吡咯衍生物∶多巴胺受体亚型特异配体 |
| US6284759B1 (en) * | 1998-09-30 | 2001-09-04 | Neurogen Corporation | 2-piperazinoalkylaminobenzo-azole derivatives: dopamine receptor subtype specific ligands |
| TR200101155T2 (tr) * | 1998-11-17 | 2001-09-21 | F. Hoffmann-La Roche Ag | 4-Aroil Piperidin CCR-3 Reseptör Antagonistleri III |
| BR9915520A (pt) * | 1998-11-20 | 2001-07-17 | Hoffmann La Roche | Antagonistas receptores ccr-3 derivados de pirrolidina |
| ATE386720T1 (de) * | 1998-11-20 | 2008-03-15 | Hoffmann La Roche | Piperidin ccr-3 rezeptor-hemmer |
| AU4157500A (en) * | 1999-03-26 | 2000-10-16 | Astrazeneca Ab | Novel compounds |
| AU5487300A (en) * | 1999-06-14 | 2001-01-02 | Neurogen Corporation | Benzylpiperazinyl-indolinylethanones |
| US6476041B1 (en) * | 1999-10-29 | 2002-11-05 | Merck & Co., Inc. | 1,4 substituted piperidinyl NMDA/NR2B antagonists |
| NZ521576A (en) * | 2000-02-29 | 2005-06-24 | Mitsubishi Pharma Corp | Novel cyclic amide derivatives |
| AU2001292276A1 (en) * | 2000-09-27 | 2002-04-08 | Toray Industries, Inc. | Nitrogen-containing compounds and ccr3 inhibitors containing the same as the active ingredient |
| AU2002216107A1 (en) * | 2000-12-19 | 2002-07-01 | F. Hoffmann-La Roche Ag | Substituted pyrrolidines as CCR-3 receptor antagonists |
| GB0203299D0 (en) * | 2002-02-12 | 2002-03-27 | Glaxo Group Ltd | Novel compounds |
| AU2003248122A1 (en) * | 2002-07-25 | 2004-02-16 | Kotobuki Pharmaceutical Co., Ltd. | Sodium channel inhibitor |
-
2004
- 2004-10-14 EP EP04790404A patent/EP1680408A2/en not_active Withdrawn
- 2004-10-14 KR KR1020067007870A patent/KR20060061393A/ko not_active Ceased
- 2004-10-14 JP JP2006536005A patent/JP2007509095A/ja active Pending
- 2004-10-14 MX MXPA06004304A patent/MXPA06004304A/es not_active Application Discontinuation
- 2004-10-14 SG SG200702988-7A patent/SG131946A1/en unknown
- 2004-10-14 RU RU2006117631/04A patent/RU2006117631A/ru not_active Application Discontinuation
- 2004-10-14 CA CA002543419A patent/CA2543419A1/en not_active Abandoned
- 2004-10-14 AU AU2004283842A patent/AU2004283842A1/en not_active Abandoned
- 2004-10-14 BR BRPI0415767-2A patent/BRPI0415767A/pt not_active Application Discontinuation
- 2004-10-14 CN CNA2004800311310A patent/CN1871222A/zh active Pending
- 2004-10-14 WO PCT/EP2004/011545 patent/WO2005040129A2/en not_active Ceased
- 2004-10-22 TW TW093132290A patent/TW200522957A/zh unknown
- 2004-10-22 AR ARP040103835A patent/AR046340A1/es unknown
- 2004-10-25 US US10/972,564 patent/US20050090504A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| MXPA06004304A (es) | 2006-06-05 |
| TW200522957A (en) | 2005-07-16 |
| WO2005040129A3 (en) | 2005-06-23 |
| SG131946A1 (en) | 2007-05-28 |
| JP2007509095A (ja) | 2007-04-12 |
| US20050090504A1 (en) | 2005-04-28 |
| AR046340A1 (es) | 2005-12-07 |
| EP1680408A2 (en) | 2006-07-19 |
| CN1871222A (zh) | 2006-11-29 |
| CA2543419A1 (en) | 2005-05-06 |
| AU2004283842A1 (en) | 2005-05-06 |
| RU2006117631A (ru) | 2007-12-10 |
| KR20060061393A (ko) | 2006-06-07 |
| WO2005040129A2 (en) | 2005-05-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0307351A (pt) | Composto, composição farmacêutica, método para tratar uma condição ou estado de doença mediados pela atividade de p38 quinase ou mediados por citocinas produzidas pela atividade de p38 quinase, uso de um composto, e, processo para preparar um composto | |
| EA200500342A1 (ru) | Гетероциклические замещённые пиперазины для лечения шизофрении | |
| DK1501507T3 (da) | Tetrahydropyranyl-cyclopentyl-tertrahydropyridopyrindin-modulatorer af kemokin-receptor-aktivitet | |
| PT1716152E (pt) | Compostos heterocíclicos fundidos e sua utilização como antagonistas do receptor metabotrópico para o tratamento de distúrbios gastrointestinais | |
| BRPI0507462A (pt) | compostos de quinolina substituìdos | |
| BR0211473A (pt) | Novos compostos | |
| DE60315146D1 (de) | Heteroarylsubstituierte biphenylderivate als inhibitoren von p38-kinase | |
| EA200600294A1 (ru) | [1,8] нафтиридин-2-оны и родственные соединения для лечения шизофрении | |
| BR0316350A (pt) | Diaminotriazóis úteis como inibidores de proteìna cinases | |
| BR0108678A (pt) | Novos compostos | |
| DK1776349T3 (da) | 2-amino-puinazolin derivater anvendelige som inhibitorer af beta-sekretase (BACE) | |
| CY1109808T1 (el) | Αρυλινδενο-πυριδινες και αρυλινδενο-πυριμιδινες και η χρηση τους ως ανταγωνιστων των υποδοχεων αδενοσινης α2α | |
| BRPI0413094A (pt) | derivados de quinolina e seu uso em terapia | |
| NO20055649L (no) | Substituert dihydrokinazolin med antiviale egenskaper | |
| BRPI0407913A (pt) | antagonistas receptores de ccr-3 | |
| PL1620425T3 (pl) | Podstawione 3-cyjanotiofenoacetamidy jako antagoniści receptora glukagonu | |
| EA200970192A1 (ru) | Производные 5,6-бисарил-2-пиридин-карбоксамида, их получение и их применение в терапии в качестве антагонистов рецепторов уротензина ii | |
| PL1789398T3 (pl) | Pochodne 2-amino-chinazoliny użyteczne jako inhibitory ß-sekretazy (BACE) | |
| BRPI0416030A (pt) | pirido-7-pirimidin-7-onas substituìdas com hidroxialquila | |
| IS8485A (is) | Notkun á setnum 2-amínótetralínum í fyrirbyggjandi meðferð á Parkinsons-veiki | |
| BRPI0409580A (pt) | compostos de quinazolina | |
| MXPA04004981A (es) | Derivados de piperazina para uso como antagonistas del receptor ccr-3 en tratamiento de asma. | |
| BRPI0411867A (pt) | tiofenilaminoimidazolinas | |
| BR0213574A (pt) | Compostos básicos lineares apresentando atividade antagonista do nk-2 e formulações contendo os mesmos | |
| BRPI0409405A (pt) | compostos 7-aza-quinazolina substituìdos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |